MedTrace Logo

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

NCT04378608 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-05-12

No results posted yet for this study

Summary

The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients

Conditions

  • Hepatitis C Virus Infection

Interventions

DRUG

OBV/PTV/r) ± ribavirin (RBV)

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Mohammed Abdel-Gabbar, Ass. Prof · Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-05
Primary Completion
2017-09-08
Completion
2017-09-08

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04378608 on ClinicalTrials.gov